Lipocine (NASDAQ:LPCN) Posts Earnings Results, Beats Estimates By $0.31 EPS

Lipocine (NASDAQ:LPCN) announced its earnings results on Thursday. The specialty pharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.31, Zacks reports. Lipocine had a negative return on equity of 64.75% and a negative net margin of 755.39%. The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $0.16 million.

Lipocine Stock Performance

Lipocine stock traded up $0.04 during mid-day trading on Friday, hitting $1.57. The company had a trading volume of 507,960 shares, compared to its average volume of 5,694,962. The business has a fifty day moving average of $1.92 and a 200 day moving average of $3.77. Lipocine has a 1 year low of $1.36 and a 1 year high of $12.37.

Insider Activity

In other news, Director John Higuchi bought 15,970 shares of Lipocine stock in a transaction dated Wednesday, September 30th. The stock was acquired at an average cost of $2.23 per share, with a total value of $35,613.10. Following the acquisition, the director owned 241,365 shares of the company’s stock, valued at approximately $538,243.95. This trade represents a 7.09% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders bought a total of 37,568 shares of company stock worth $82,174 over the last 90 days. Company insiders own 4.69% of the company’s stock.

Analyst Ratings Changes

LPCN has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Lipocine in a report on Tuesday, September 22nd. HC Wainwright restated a “neutral” rating and issued a $4.00 price target on shares of Lipocine in a research report on Monday, September 21st. Weiss Ratings raised Lipocine from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 29th. Finally, Wall Street Zen upgraded Lipocine from a “sell” rating to a “hold” rating in a research report on Saturday, July 18th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $4.00.

Lipocine Company Profile

Lipocine Inc is a biopharmaceutical company focused on developing oral therapies for conditions with significant unmet medical needs. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and clinical performance of active pharmaceutical ingredients that may otherwise have limited effectiveness when taken orally.

Lipocine’s lead product is Tlando, an oral testosterone replacement therapy containing testosterone undecanoate. The U.S. Food and Drug Administration approved Tlando in 2022 for testosterone replacement therapy in adult males with hypogonadism associated with an underlying medical condition.